Great progress has been made in the field of precision medicine and targeted therapy development. However, the full value proposition of this approach has not yet been realized. A key challenge is that there has not been strong alignment between the therapy and diagnostic interests and business models.
We are now at the precipice of seeing a shift in the business case for precision medicine. To be successful though we must answer several important questions. What are the key features of a propriety diagnostic tool that would enable isolation of a unique market opportunity? What is the business model that should be deployed to incentivize investment in this type of tool? In this paper, we will outline the answers to these questions and provide some examples of exciting technologies which may tap this potential.
By providing my email address, I agree to ClearView's online policies